Although the mechanism by which proteasome inhibitors reduce FOXM1 protein levels is unclear, bortezomib, a first-generation proteasome inhibitor approved for the treatment of multiple myeloma, is reported to suppresses FOXM1 mRNA and protein [17]. Here, FOXM1 is linked to plasma cell myeloma.